One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Hims & Hers Health stock rocketed to a new all-time high Thursday as retail interest continued after its successful Super ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...